-
Mashup Score: 5Study Finds Ruxolitinib Effective, Safe for Children With AD - 6 month(s) ago
There were no significant safety signals in the younger pediatric population, and ‘no treatment-emergent adverse events suggestive of systemic JAK inhibition,’ Dr Lawrence Eichenfield said.
Source: www.medscape.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 0Incyte Announces Expanded TRuE-AD3 Data at EADV - 7 month(s) ago
The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0Treatment-Related Acne After Ruxolitinib Application for Vitiligo Occurred in Patients Without History of Acne - 7 month(s) ago
Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0
According to the phase 2 MANIFEST trial, the combination of pelabresib plus ruxolitinib demonstrated durable improvements in spleen volume, symptom burden, and disease-modifying activity among patients with JAK inhibitor naïve myelofibrosis.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Topical Ruxolitinib for Vitiligo: First-Year Experiences - 8 month(s) ago
Some dermatologists recommend combining the treatment with phototherapy and advise that results can take many months to see.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Ruxolitinib Demonstrates Superior Benefits in PV Resistant or Intolerant to Hydroxycarbamide | ASH Clinical News | American Society of Hematology - 9 month(s) ago
Linda Kossoff is a medical writer and editor based in Los Angeles. Ruxolitinib treatment resulted in superior complete response (CR), event-free survival (EFS), and molecular response compared with best available therapy (BAT) in patients with polycythemia vera (PV) that is resistant or intolerant to hydroxycarbamide (HC-INT/RES), according to a study published in the Journal of Clinical Oncology. PV is a myeloproliferative neoplasm driven by JAK2 mutations and characterized by erythrocytosis, thromboembol
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Ruxolitinib Granted Marketing Authorization in United Kingdom - 10 month(s) ago
The authorization comes just over 2 months after the drug’s approval in the European Union.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0
Following promising phase 1 study results, the combination of selinexor and ruxolitinib is being evaluated in a phase 3 trial in patients with myelofibrosis.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Combined Pelabresib, Ruxolitinib Improved Splenomegaly in JAK Inhibitor Treatment-Naïve MF | ASH Clinical News | American Society of Hematology - 10 month(s) ago
Skip Nav Destination June 1, 2023 Katie Robinson is a freelance medical writer based in New York. In patients with myelofibrosis (MF) who are Janus kinase (JAK) inhibitor treatment-naïve, the combination of pelabresib and…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Treatment with the topical Janus kinase (JAK) inhibitor #ruxolitinib appears to be as safe and effective for the control of atopic dermatitis (AD) in children aged 2-11 years as previously shown in adolescents and adults. https://t.co/wsnOKFnMr4